未知生产厂商
Palifermin is a form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy.
Palifermin is a form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy.
Palifermin has been shown to protect oral and intestinal epithelia from the effects of radiation and chemotherapy, though the exact mechanism is not well understood. As a recombinant keratinocyte growth factor (KGF), palifermin may promote cell proliferation, reducing the severity of oral mucositis in patients in the relevant treatment groups. Agonism of fibroblast growth factor 2 may be predominantly responsible for this effect. The endogenous form if palifermin is expressed in the kidney of rats.
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
